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Abstract
Background: Nasal gene expression profiling is a promising method to characterize COPD non-invasively. We
aimed to identify a nasal gene expression profile to distinguish COPD patients from healthy controls. We
investigated whether this COPD-associated gene expression profile in nasal epithelium is comparable with the
profile observed in bronchial epithelium.
Methods: Genome wide gene expression analysis was performed on nasal epithelial brushes of 31 severe COPD
patients and 22 controls, all current smokers, using Affymetrix Human Gene 1.0 ST Arrays. We repeated the gene
expression analysis on bronchial epithelial brushes in 2 independent cohorts of mild-to-moderate COPD patients
and controls.
Results: In nasal epithelium, 135 genes were significantly differentially expressed between severe COPD patients
and controls, 21 being up- and 114 downregulated in COPD (false discovery rate < 0.01). Gene Set Enrichment
Analysis (GSEA) showed significant concordant enrichment of COPD-associated nasal and bronchial gene
expression in both independent cohorts (FDRGSEA < 0.001).
Conclusion: We identified a nasal gene expression profile that differentiates severe COPD patients from controls. Of
interest, part of the nasal gene expression changes in COPD mimics differentially expressed genes in the bronchus.
These findings indicate that nasal gene expression profiling is potentially useful as a non-invasive biomarker in
COPD.
Trial registration: ClinicalTrials.gov registration number NCT01351792 (registration date May 10, 2011), ClinicalTrials.
gov registration number NCT00848406 (registration date February 19, 2009), ClinicalTrials.gov registration number
NCT00807469 (registration date December 11, 2008).
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Background
Chronic obstructive pulmonary disease (COPD) is one of
the most common chronic diseases affecting over 10% of
adults older than 65 years worldwide [1]. It is characterized
by incompletely reversible airflow obstruction, which re-
sults in reduced quality of life and increased mortality.
COPD is currently the fourth leading cause of death world-
wide, according to the World Health Organization [2].
Some genetic factors, such as alpha-1 anti-trypsin defi-
ciency, and environmental exposures, such as cigarette
smoking, are well-established contributors to COPD, yet
the precise molecular mechanisms of the disease remain
to be elucidated. Genome-wide gene expression profiling
offers opportunities to develop new insights in the origins
of COPD based on molecular features.
The airway epithelium is the initial site of exposure
to cigarette smoke and reflects molecular changes asso-
ciated with both cigarette smoke exposure and smoking-
associated lung disease. We have previously demonstrated
that the bronchial airway epithelium responds to cigarette
smoke exposure with characteristic alterations in gene ex-
pression [3]. Building upon this observation, we identified
a bronchial airway gene expression signature associated
with COPD and disease severity that is similarly altered in
COPD-affected lung tissue [4]. These data suggest that
bronchial gene expression obtained by bronchoscopy may
be applied to monitor disease activity in COPD. However,
the relative invasiveness of this procedure precludes its
use in large populations. We therefore characterized the
upper airway genomic response to cigarette smoke expos-
ure by profiling epithelial cells collected by brushing the
inferior turbinate of the nose. Using paired bronchial and
nasal airway samples obtained from the same healthy
individuals, we showed that smoking-induced changes in
bronchial airway gene expression are similarly altered in
the nasal epithelium [5]. Therefore, nasal epithelial gene
expression profiling could potentially function as a
non-invasive biomarker in COPD.
In the present study, we investigated whether gene ex-
pression profiling of the nasal epithelium can distinguish
between patients with and without COPD. Additionally,
we established whether COPD-associated gene expres-
sion changes in nasal epithelium reflect those occurring
in the bronchial epithelium.
Methods
The online supplement provides additional details and a
flowchart of the identification cohort and comparator
cohorts (online Additional file 1: Figure E1).
Identification cohort, sample collection and processing
The local ethical committees approved the studies and all
included subjects gave their written informed consent.
COPD patients were recruited in the University Medical
Center Groningen (UMCG) and seven other participating
hospitals in The Netherlands between 2011 and 2012.
From this study, we only included current smokers
aged 40 years and older with at least 10 pack years, a
forced expiratory volume in 1 s (FEV1)/forced vital
capacity (FVC) < 0.7 and an FEV1 < 60% predicted.
Controls were recruited in the UMCG between 2009
and 2012, including only current smokers aged 40 years
and older with normal pulmonary function (i.e. post-
bronchodilator FEV1/FVC > lower limit of normal, ab-
sence of bronchial hyperresponsiveness and reversibility
of FEV1 to salbutamol <10% predicted). Spirometry and
body plethysmography measurements were performed ac-
cording to international guidelines [6, 7]. Symptom scores
were assessed using the Clinical COPD Questionnaire
(CCQ) [8].
Nasal epithelial brushings were obtained using a soft
cytology brush sampling the inferior turbinate of the
nose [5, 9]. Total RNA was isolated and microarray
hybridization to Affymetrix Human Gene 1.0 ST Arrays
was performed.
Data normalization, preprocessing and analysis
Statistical analyses were performed using R version 3.3.2.
The quality of the microarray hybridization was assessed
as previously described [4]. Nasal gene expression pro-
files associated with COPD were identified using a linear
regression model with the log2-transformed expression
of each gene as dependent variable, and COPD, age, gen-
der, packyears, RNA integrity number (RIN), and the
first 4 principal components (PCs) as independent vari-
ables. We adjusted for PCs to reduce technical variation
in the microarray data (online Additional file 1). A
Benjamini-Hochberg False Discovery Rate (FDR) proced-
ure was applied to account for multiple testing, with an
FDR < 0.01 indicating statistical significance [10].
Comparison of COPD-associated gene expression changes
in the nasal and bronchial epithelium
We compared nasal COPD-associated gene expression with
bronchial COPD-associated gene expression in two inde-
pendent datasets of bronchial brushings (comparator co-
hort 1 and comparator cohort 2 as described below), using
Gene Set Enrichment Analysis (GSEA) version 2.2.4 [11].
The local ethical committees approved the two studies and
all included subjects gave their written informed consent.
– Comparator cohort 1 was a previously published
dataset of bronchial airway gene expression in
current and former smokers with and without
moderate-to-severe COPD (GSE37147) [4].
– Comparator cohort 2 was an independent cohort of
current and former smokers with and without
moderate-to-severe COPD who participated in a
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previous study in the UMCG [12, 13]. COPD was
defined as FEV1/FVC ≤ 0.7. Bronchial brushes were
taken during bronchoscopy and RNA was isolated
and processed as described in the online supplement.
We performed GSEA for genes associated with COPD
in nasal and bronchial epithelium. First, we investigated
COPD-associated nasal gene expression with COPD-
associated bronchial gene expression. To this end, bron-
chial genes were ranked according to the strength of their
association with COPD (t-value), and compared to signifi-
cantly COPD-associated up- and downregulated genes in
nasal epithelium.
Pathway analysis
We compared COPD-associated nasal and bronchial
gene expression to gene-sets generated from the Kyoto
Encyclopedia of Genes and Genomes (KEGG). A
FDRGSEA < 0.25 was considered statistically significant.
In addition, to identify more specific biological processes
we performed Gene Ontology enrichment analyses
(GOrilla) on COPD-associated genes exhibiting dif-
ferential expression in nasal samples.
Results
Study populations
The identification cohort consisted of 31 COPD patients
and 22 controls with nasal epithelial brushes. The com-
parator cohorts contained in total 97 COPD patients
and 171 controls with bronchial epithelial brushes.
Clinical characteristics are presented in Table 1.
COPD-associated genes in nasal epithelium
Nasal epithelial gene expression levels of 135 genes were
significantly altered in individuals with COPD versus con-
trols (FDR <0.01; 21 upregulated and 114 downregulated).
The top-10 most significantly upregulated genes were
SHROOM1, STARD13, CMTM1, SHC4, RRBP1, MUC1,
ARHGEF16,TEP1,TRIM3 and GPRC5C. The top-10 most
significantly downregulated genes were NPHP1, CFAP206,
Table 1 Characteristics of the identification cohort (nasal epithelial brushes) and comparator cohorts (bronchial epithelial brushes)
Identification cohort Comparator cohorts
Nasal brushes Bronchial brushes (cohort 1) Bronchial brushes (cohort 2)
COPD
(n = 31)
Control
(n = 22)
p COPD
(n = 87)
Control
(n = 151)
p COPD
(n = 10)
Control
(n = 20)
p
Age, years 61 (8) 52 (8) <0.01 65 (6) 64 (6) 0.25 67 (5) 55 (10) <0.01
Male gender, n (%) 21 (68%) 14 (64%) 0.76 52 (60%) 83 (55%) 0.50 10 (100%) 17 (85%) 0.20
Smoking status
Current smoking, n (%) 31 (100%) 22 (100%) 1 30 (35%) 69 (46%) 0.10 8 (80%) 19 (95%) 0.20
Ex smoking, n (%) 0 (0%) 0 (0%) 57 (66%) 82 (54%) 2 (20%) 1 (5%)
Packyears 39 (18) 29 (12) 0.03 51a (25) 47a (19) 0.11 31b (22-45) 26b (24-36) 0.57
ICS use, n (%) 27 (87%) – <0.01 18 (21%) 7 (5%) <0.01 8 (80%) 0 (0%) <0.01
FEV1
c, % predicted 31 (6) 102 (11) <0.01 60 (14) 93 (13) <0.01 62b (52-68) 102b (97-114) <0.01
FEV1/FVC, % 34 (8) 75 (4) <0.01 56 (9) 75 (6) <0.01 50
b (42-56) 73b (71-83) <0.01
GOLD classificationc
GOLD 1, n (%) 0 (0%) – – 0 (0%) – – 1 (10%) – –
GOLD 2, n (%) 2 (6%) – – 68 (78%) – – 8 (80%) – –
GOLD 3, n (%) 22 (71%) – – 17 (20%) – – 1 (10%) – –
GOLD 4, n (%) 7 (23%) – – 2 (2%) – – 0 (0%) – –
TLC, % predicted 132 (17) 105 (10) <0.01 n/a n/a – n/a n/a –
RV/TLC, % 62 (7) 30 (3) <0.01 n/a n/a – n/a n/a –
CCQ 2.4 (0.9) 0.4 (0.3) <0.01 n/a n/a – n/a n/a –
Allergic rhinitis, n (%) 1 (3%) 5 (23%) 0.07 n/a n/a – n/a n/a –
Nasal CS use, n (%) 2 (7%) 1 (5%) 0.99 n/a n/a – n/a n/a –
All values are presented as mean with standard deviation, unless stated otherwise; p-values reflect differences between COPD and controls
aMissing packyears for 5 subjects with COPD and 11 controls
bMedian with interquartile range
cpostbronchodilator, except for 1 subject in the identification cohort for which postbronchodilator FEV1 was not available, we show prebronchodilator FEV1
instead (32%); for all subjects in cohort 1, only prebronchodilator FEV1 was available
ICS Inhaled corticosteroids, FEV1 Forced expiratory volume in 1 s, FVC Forced vital capacity, GOLD Global initiative for chronic obstructive lung disease, TLC Total
lung capacity, RV Residual volume, CCQ Clinical COPD Questionnaire, CS Corticosteroids, n/a Not available
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C11orf70, CCDC113, CSE1L, FAM83B, LTV1, GMNN,
SERPINB5 and AKAP14. Figure 1 shows a heatmap of all
135 significantly differentially expressed genes between
COPD patients and controls, while Table E1 in online
Additional file 1 presents all 135 differentially expressed
genes.
COPD patients were recruited at multiple study sites
within the Netherlands, whereas controls were recruited
in the UMCG only. To exclude the possibility that our
results were due to study site-specific factors in nasal
epithelial sampling, we performed a sub-analysis in nasal
epithelial samples derived from individuals with COPD
recruited in the UMCG (n = 12) and comparing them to
the non-COPD controls also recruited from the UMCG
(n = 22). We also compared individuals with COPD re-
cruited at other study sites (n = 19) with the non-COPD
controls recruited in the UMCG. We used GSEA to com-
pare COPD-associated gene expression in non-UMCG
COPD patients with COPD-associated gene expression in
UMCG COPD patients. GSEA showed that the COPD-
associated gene expression profiles were comparable be-
tween UMCG and non-UMCG COPD patients (FDRGSEA <
0.001; online Additional file 1: Figure E2). In line with the
above GSEA results, plots of the principal component
analysis including only COPD patients revealed an even
distribution of subjects across all study recruitment sites
(online Additional file 1: Figure E3), indicating that the
study site where the nasal epithelial brushes were collected
did not have an effect on gene expression levels.
Comparison of COPD-associated gene expression in the
nasal and bronchial epithelium
We assessed whether COPD-associated gene expression
in the nasal epithelium is related to the COPD-associated
gene expression changes in the bronchial epithelium. To
this end, we explored the direct overlap between COPD-
associated genes in nasal and bronchial epithelium in
comparator cohort 1. Of the 135 genes significantly differ-
entially expressed in nasal epithelium, 9 out of 21 genes
that were significantly upregulated with COPD in nasal
epithelium (FDR < 0.01), were also significantly upregu-
lated with COPD in bronchial epithelium (FDR < 0.01). Of
the 114 genes significantly downregulated with COPD in
nasal epithelium, 19 were also significantly downregulated
with COPD in bronchial epithelium (FDR < 0.01; online
Additional file 1: Table E2). By chance, we would have
expected an overlap of 1 gene at a FDR < 0.01, yet we
identified 28 overlapping genes in nasal and bronchial
epithelium (Chi square statistic p-value <0.01), providing
suggestive evidence that our findings are not mere due to
chance.
Next, we used GSEA to compare COPD-associated
nasal epithelial gene expression with COPD-associated
bronchial epithelial gene expression in the 2 independent
comparator cohorts of subjects with and without COPD.
Genes significantly upregulated in nasal epithelium of in-
dividuals with COPD were significantly enriched among
genes upregulated in bronchial epithelium in COPD in
both cohorts (FDRGSEA < 0.001, Fig. 2a and b). Similarly,
genes significantly downregulated in nasal epithelium
in COPD were significantly enriched among genes
downregulated in bronchial epithelium in COPD
(FDRGSEA < 0.001, Fig. 2c and d).
Similarities in pathway enrichment among COPD-
associated gene expression in nasal and bronchial
epithelium
We identified 6 KEGG pathways that were significantly
enriched (FDRGSEA ≤ 0.25) in the nasal epithelium from
the identification cohort and in the bronchial epithelium
of both comparator cohorts (Table 2). These included 2
pathways enriched among genes upregulated in COPD
(O-glycan biosynthesis and glycosphingolipid biosyn-
thesis – lacto and neolacto series) and 4 pathways
enriched among genes downregulated in COPD (RNA
degradation, DNA replication, propanoate metabolism
and tight junction) (online Additional file 1: Tables E3
and E4). Additionally, gene ontology enrichment analyses
confirmed significant enrichment of downregulated genes
involved in cell cycle and translation, such as negative
regulation of G2/M transition of mitotic cell cycle and
translational initiation, as well as pathways involved in
ciliary function (online Additional file 1: Table E5). For
upregulated genes in nasal epithelium, no significant
Fig. 1 Heatmap of gene expression significantly associated with
COPD status. Between COPD and controls, 135 genes were
significantly differentially expressed: 114 genes were significantly
down- and 21 genes were significantly upregulated in
COPD (FDR < 0.01)
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biological processes were identified. These results may
reflect a slower rate of epithelium renewal and ciliary
dysfunction in COPD.
We aimed to identify genes that play an important role
in these 6 KEGG pathways in nasal and bronchial epithe-
lium. Using GSEA we identified the leading-edge subset of
genes (online Additional file 1: Figure E4) for each of the
pathways significantly enriched in the three cohorts, and
took the overlap of the leading edge genes from these ana-
lyses that were also significantly differentially expressed
both in nasal epithelium (p-value < 0.05) and in bronchial
epithelium (cohort 1; FDR < 0.05) (online Additional file 1:
Table E6 and E7). Fifteen genes fulfilled above criteria,
suggesting they may play a role in COPD (Table 2).
Discussion
We performed gene expression profiling of the nasal epi-
thelium in smoking individuals with and without COPD
and identified a nasal epithelial gene expression profile
associated with COPD. Furthermore, we provide sug-
gestive evidence that the COPD-associated nasal gene
expression profile overlaps with the COPD-associated
bronchial gene expression profile, supporting the con-
cept of a ‘united airway field of injury’. These findings
suggest that sampling of nasal epithelium may be useful
to study underlying mechanisms of COPD and to develop
easily accessible non-invasive biomarkers for disease clas-
sification, prognosis and therapeutic monitoring.
There is a high need for an epigenetic biomarker that
provides information on disease activity of respiratory
diseases, but studies addressing this are limited. A recent
study by Obeidat et al. explored expression of 127
emphysema-related genes in lung tissue, bronchial epi-
thelium and peripheral blood in relation to lung function
(FEV1 and FEV1/FVC) [14]. Of the 40 genes associated
with lung function in peripheral blood (FDR 0.1), 29
(73%) were overlapping with lung function-associated
genes in lung tissue. Of these 29 genes, 4 (13%) had a
similar direction in blood and lung tissue. Additionally,
they found 13 (33%) lung-function associated genes
overlapping between peripheral blood and bronchial epi-
thelium, of which 8 (20%) exhibited changes in similar
direction. Of interest, Obeidat et al. used the same bron-
chial epithelium cohort as investigated in our study [4].
We found that out of 135 genes associated with COPD
in nasal epithelium, 28 genes (21%) overlapped with
genes associated with COPD in bronchial epithelium in
similar direction (FDR 0.01), which is in line with the
results of Obeidat et al. Nevertheless there are some
considerable differences between the studies. In the first
Fig. 2 Gene set enrichment analysis showing that nasal gene expression associated with COPD resembles bronchial gene expression. The colored
bars represent the ranked t-values of the association of bronchial gene expression with COPD of ~20.000 genes: red represents a positive association
whereas blue represents a negative association with COPD. The black vertical lines each represent a significantly differentially expressed gene in nasal
epithelium, which are ordered across the ranked bronchial genes. The height of the black lines represents the running enrichment scores of the gene
set enrichment analysis. Significant differentially expressed genes at a FDR cut-off of <0.01 are shown. a Upregulated genes in nasal epithelium
(n = 21) were significantly enriched among upregulated genes in bronchial epithelium in cohort 1, b Upregulated genes in nasal epithelium (n = 21)
were significantly enriched among upregulated genes in bronchial epithelium in cohort 2, c Downregulated genes in nasal epithelium (n = 114) were
significantly enriched among downregulated genes in bronchial epithelium in cohort 1, d Downregulated genes in nasal epithelium (n = 114) were
significantly enriched among genes downregulated in bronchial epithelium in cohort 2
Boudewijn et al. Respiratory Research  (2017) 18:213 Page 5 of 10
place, our study reports results of a genome wide gene
expression analysis to identify COPD-associated genes,
while Obeidat et al. conducted a targeted analysis of 127
genes known to be related to emphysema in lung tissue.
The targeted approach might have increased the chance
of finding differentially expressed genes, but, on the
other hand, it disregards expressed genes that are related
to features of COPD other than emphysema, such as
small airways disease and bronchitis. Additionally, we in-
vestigated genes associated with COPD as dichotomous
outcome, while Obeidat et al. did not investigate COPD
as a disease entity, but investigated FEV1 and FEV1/FVC
as continuous measures. The genes identified by Obeidat
et al. are therefore more likely to be related to the sever-
ity of airway obstruction while the genes identified in
our study are likely to be related to COPD in general. Of
importance, we applied a stringent FDR of 0.01 while
the former study applied an FDR of 0.1, which might
have resulted in more false-positive findings among
genes identified in peripheral blood. Also, since smoking
status significantly affects gene expression, we only se-
lected current smokers for our gene expression analysis
in nasal epithelium, while Obeidat et al. investigated
both current- and ex-smokers. In conclusion, both gene
expression in nasal epithelium and peripheral blood ap-
pear promising as biomarkers in COPD. Future studies
should address the direct comparison of gene expression
in nasal epithelium and blood in relation to COPD, in
which special attention should be given to a similar
study design. These studies will be necessary to deter-
mine which of these tissues is most suitable to serve as a
biomarker in respiratory diseases.
A number of the genes identified in the present study
have been previously considered as candidates that asso-
ciate with features of COPD, such as MUC1, CREB3L1,
DSP, NPHP1, CFAP206 and CCDC113 [15–28]. Among
the top-10 significantly upregulated genes in nasal epi-
thelium of COPD patients is Mucin 1 (MUC1). MUC1 is
Table 2 Common KEGG pathways and leading-edge genes associated with COPD identified by GSEA (FDRGSEA ≤ 0.25) in nasal and
bronchial epithelium
Nasal Bronchial (cohort 1) Bronchial (cohort 2)
t-value p value‡ t-value FDR p value t-value p value‡
Enriched pathways for genes upregulated in COPD
O-glycan biosynthesis (KEGG) 0.01# <0.01# 0.02#
GALNT6 3.00 <0.01 3.21 0.02 1.57 0.13
GALNT12 3.25 <0.01 3.32 0.01 3.83 <0.01
B3GNT6 2.51 0.02 3.55 <0.01 2.92 <0.01
ST6GALNAC1 2.65 0.01 3.44 <0.01 1.91 0.07
Glycosphingolipid biosynthesis (KEGG)a 0.04# <0.01# 0.11#
FUT3 2.13 0.04 6.76 <0.01 2.68 0.01
FUT6 2.72 0.01 6.22 <0.01 2.77 0.01
B4GALT4 2.11 0.04 4.15 <0.01 0.12 0.90
B3GNT3 3.32 <0.01 5.06 <0.01 1.36 0.19
Enriched pathways for genes downregulated in COPD
DNA replication (KEGG) <0.01# 0.09# 0.19#
RFC3 −2.36 0.02 −3.82 <0.01 −2.43 0.02
RNA degradation (KEGG) <0.01# 0.06# 0.06#
Propanoate metabolism (KEGG) 0.13# 0.20# 0.09#
LDHB −3.93 <0.01 −3.88 <0.01 −1.12 0.28
ACADM −2.71 0.01 −6.06 <0.01 −2.14 0.04
ALDH3A2 −2.53 0.02 −4.57 <0.01 −1.15 0.26
Tight junction (KEGG) 0.13# 0.21# 0.24#
CLDN16 −2.33 0.02 −3.56 <0.01 −2.76 0.01
CTNNB1 −3.33 <0.01 −3.18 0.02 −1.65 0.11
EPB41L2 −2.64 0.01 −6.03 <0.01 −1.67 0.11
Above leading-edge genes of the 6 significantly enriched KEGG pathways in all three cohorts were significantly differentially expressed between COPD patients
and controls both in nasal and bronchial epithelium (cohort 1). The t-value reflects the direction and the strength of the difference in expression of a gene
between COPD and controls, FDR False discovery rate, #FDRGSEA q value;
‡nominal p-value. alacto and neolacto series
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a membrane-associated mucin which is expressed in
nearly all human glandular epithelial cells including the
airway epithelium [15]. It is thought that MUC1 exerts
anti-inflammatory effects upon infection with pathogens
by suppressing pro-inflammatory cytokines such as
Tumor Necrosis Factor-alpha (TNF-α) [16, 17]. Of inter-
est, plasma and sputum levels of KL-6, a glycoprotein
classified as a human MUC1 mucin, are higher in COPD
patients than healthy smokers and non-smokers [18],
which is in line with our findings as we found MUC1 to
be upregulated in nasal epithelium of COPD patients.
Additionally, cAMP Responsive element Protein-Like 1
(CREB3L1) is a transcription factor involved in the un-
folded protein response during endoplasmic reticulum
stress. It has been proposed that CREB3L1 has a central
role in mucus production, since it is associated with
MUC5AC expression, an important mucin secreted by
the airway epithelium [19]. Furthermore, CREB3L1 con-
tributes to collagen-containing extracellular matrix pro-
duction upon simulation with transforming growth
factor beta (TGF-β) [20]. Increased mucus production
and airway remodeling are key features of COPD [21,
22], therefore upregulation of CREB3L1 can be envis-
aged to play a role in the pathophysiology of COPD.
Among the top-10 significantly downregulated genes in
nasal epithelium in COPD are nephrocystin 1 (NPHP1),
cilia and flagella associated protein 206 (CFAP206) and
coiled-coil domain containing 113 (CCDC113). These 3
genes have in common that they are all involved in cil-
liagenesis or cilia function. For example, nephrocystin 1
is localized at the ciliary transition zone of respiratory
cilia [23]. Next, CFAP206 has recently been identified
as a player in cilium motility through its role in the as-
sembly of the axonemal radial spokes [24]. Finally,
CCDC113 is a centrosome-associated protein and has a
function in cilia formation as depletion of CCDC113 in
retinal pigmented epithelial (RPE1) cells led to reduc-
tion of cilium formation [25]. In COPD, ciliary function
is impaired which leads to decreased mucociliary trans-
port [26]. We found cilia-associated genes to be down-
regulated in COPD, which might contribute to this
process. Another COPD-associated downregulated gene
in nasal epithelium is Desmoplakin (DSP), a gene recently
discovered to be associated with COPD in a large GWAS
[27]. Of interest, in the latter study COPD-linked variants
in DSP were associated with decreased expression of DSP
in lung tissue based on expression quantitative trait loci
(eQTL) analyses, compatible with our results showing de-
creased expression in nasal epithelium of COPD patients.
DSP is one of the important components of desmosomes,
a structure that is important in (epithelial) cell adhesion
and barrier function [28]. Although studies on the func-
tional role of DSP in COPD are lacking, one could specu-
late that downregulation of DSP and, therefore, decreased
epithelial barrier function contributes to the mechanisms
underlying COPD.
We identified 6 KEGG-pathways that are significantly
enriched for genes associated with COPD in both nasal
and bronchial epithelium. We identified 4 KEGG path-
ways that are universally and significantly downregulated
in COPD: RNA degradation, DNA replication, propano-
ate metabolism and tight junction. Of interest, our gene
ontology enrichment analysis confirmed downregulation
of pathways involved in translation and cell cycle, such
as translational initiation and negative regulation of G2/M
transition of mitotic cell cycle. It has been demonstrated
that cell proliferation is reduced in bronchial epithelial
cells and fibroblasts of patients with emphysema com-
pared to controls [29–31], which is in line with our results
from the KEGG and gene ontology pathway analyses.
Two pathways are significantly upregulated in both nasal
and bronchial epithelium: O-linked glycan biosynthesis
and glycosphingolipid biosynthesis. O-linked glycan bio-
synthesis is a posttranslational process during which carbo-
hydrates (glycans) are attached to proteins. Interestingly,
mucin-type O-glycans are the most common form of
glycans present in humans [32]. Mucins are highly glyco-
sylated proteins, which form the core structure of mucus.
It could be speculated that the observed upregulation of
the O-linked biosynthesis pathway in epithelial cells con-
tributes to increase in mucus production, one of the key
features of COPD pathophysiology. Glycosphingolipids are
membrane lipids (ceramide) to which a glycan is attached.
They function as structure elements in the cell membrane
and as mediators in cell-cell interaction [33]. Recent stud-
ies of our group have shown that concentrations of (glyco)-
sphingolipids are increased in sputum of COPD patients
[34]. Another study describing gene expression in periph-
eral blood mononuclear cells of COPD patients showed
that the sphingolipid metabolism pathway is signifi-
cantly upregulated in COPD individuals [35]. Add-
itionally, higher blood (glyco)sphingolipids levels are
associated with more extensive emphysema and more
frequent exacerbations [36]. In combination with our
novel findings in nasal epithelial cells, the role of
glycosphingolipids appears important in COPD, and
the exact contribution to (sub)phenotypes of COPD
and targets for possible treatments needs to be further
unraveled.
Fifteen genes were of specific interest as they were asso-
ciated with COPD in both nasal and bronchial epithelium
and additionally contributed to significantly enriched
pathways associated with COPD. Of the upregulated genes,
fucosyltransferase 3 (FUT3) and fucosyltransferase 6
(FUT6) are involved in the modification of proteins
and lipids, i.e. the attachment of fucose. Fucosylation
is increasingly recognized as an important player in
cell-cell communication [37, 38]. For example, TNF-α,
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a proinflammatory cytokine, increases expression of FUT3
and FUT6 in human bronchial mucosa, suggesting a role
for fucosyltransferases in airway inflammation [39]. Of
interest, expression of FUT3 and FUT6 is associated with
the major airway mucin MUC5AC [19]. Of the downregu-
lated genes, Replication Factor C-3 (RFC3) forms, together
with its family members RFC 1, RFC2, RFC4 and RFC5, a
protein complex involved in the regulation of DNA repli-
cation and DNA damage repair. RFC complexes can func-
tion as checkpoints that delay DNA replication in case of
DNA damage [40, 41]. Of interest, RFC1, RFC2 and RFC4
were significantly downregulated (nominal p value <0.05)
in nasal epithelium as well; however, only RFC1 was also
significantly downregulated in bronchial epithelium.
Downregulation of RFC3 has been associated with lung-,
gastric- and colorectal cancer [42, 43], but it might also
play a role in COPD as oxidative stress due to cigarette
smoke induces DNA damage.
The strength of our study is the use of an identifica-
tion cohort to determine a COPD-associated nasal gene
expression signature and the verification of this signa-
ture in two independent cohorts. We selected only
current smokers for the analyses, which led to a true
reflection of COPD-induced gene expression, hereby
avoiding contamination of the results caused by differ-
ences in smoking status among patients. Furthermore,
by selecting pathways and genes involved in all three
cohorts, the probability is high that our findings reflect
true biological mechanisms. A limitation of our study is
the use of inhaled corticosteroids (ICS) among COPD
patients, which was absent in healthy controls. Although
ICS use confounds the primary analysis of nasal gene
expression in this study, we addressed this issue by
assessing whether COPD-associated nasal gene expres-
sion changes are similar to that observed in the bronchial
airway using an independent dataset of 238 individuals
(comparator cohort 1) where only a minority of individ-
uals with COPD used ICS. Another possible limitation of
our study is that we compared nasal epithelium of severe
COPD patients with bronchial epithelium of moderate-to-
severe COPD patients. It would be of added value to study
matched nasal and bronchial samples of the same individ-
ual, in order to obtain the most appropriate comparison
between nasal and bronchial gene expression. These data
were not available in our study. However, despite the
dissimilarity in COPD severity of the patients with either
nasal or bronchial samples, we still found overlap in gene
expression between the nose and the bronchus, suggesting
a ‘shared’ gene expression signature that is relevant to
COPD, regardless of disease severity. It is possible that
distinct COPD phenotypes, such as emphysema, small
airway disease and chronic bronchitis, have their own
specific gene expression changes next to this shared signa-
ture, which needs to be explored in future research.
Conclusion
In conclusion, we demonstrate that the nasal epithelium
is a suitable site to detect COPD-associated gene expres-
sion alterations. Of interest, we show supportive evi-
dence that this nasal epithelial gene expression profile
overlaps with COPD-associated bronchial epithelial gene
expression. Our findings underscore the hypothesis that
the upper and lower airways have a shared COPD-
associated gene expression profile, a so-called ‘united
airway field of injury’. Thus nasal gene expression, that
is feasible given the ease of access to nasal epithelium,
provides the opportunity to explore other applications
in future research, such as the diagnosis of distinct
molecular phenotypes of COPD and monitoring of
disease progression and interventions.
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